MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

grant a product specific waiver

MHRA-102221-PIP01-25

Scope of the Application

Active Substance(s)

Zanzalintinib

Condition(s)

Treatment of colorectal cancer, Treatment of renal cell carcinoma

Pharmaceutical Form(s)

Tablet

Route(s) of Administration

ORAL USE

Name / Corporate name of the PIP applicant

Exelixis, Inc.

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Exelixis, Inc. submitted to the licensing authority on 18/11/2025 11:58 GMT an application for a

The procedure started on 02/12/2025 13:27 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to grant a product specific waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-102221-PIP01-25

Of 24/02/2026 10:26 GMT

On the adopted decision for Zanzalintinib (MHRA-102221-PIP01-25) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Granting a waiver in all age groups for the listed condition(s)

This decision applies to a for Zanzalintinib, Tablet , ORAL USE .

This decision is addressed to Exelixis, Inc., 1851 Harbor Bay Parkway, Alameda, UNITED STATES OF AMERICA, 94502

ANNEX I

1. Waiver

1.1 Condition:

Condition 1: Treatment of colorectal cancer The waiver applies / applied to: Paediatric Subset(s): All subsets of the paediatric population from birth to less than 18 years of age Pharmaceutical form(s): Tablet Route(s) of administration: ORAL USE Reason for granting waiver: on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s). Condition 2: Treatment of renal cell carcinoma The waiver applies / applied to: Paediatric Subset(s): All subsets of the paediatric population from birth to less than 18 years of age Pharmaceutical form(s): Tablet Route(s) of administration: ORAL USE Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Not Applicable

2.2 Indication(s) targeted by the PIP:

Not Applicable

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

Not Applicable

2.4 Pharmaceutical Form(s):

Not Applicable

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures		
Non-Clinical Studies		
Clinical Studies		
Extrapolation, Modeling & Simulation Studies		
Other Studies		
Other Measures		

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	
Date of completion of the paediatric investigation plan:	
Deferral of one or more studies contained in the paediatric investigation plan:	